CC
MACK

Centiva Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Centiva Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-187,803
Closed -$2.32M – 2402
2023
Q3 		$2.32M Buy
+187,803
New +$2.27M 0.05% 342

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Centiva Capital's MACK Position: Q4 2023 in Review

Centiva Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2023, closing a stake of 187,803 shares — an estimated $2.32M sold.

Centiva Capital first reported a position in MACK in Q3 2023 and held it in 1 quarter. The position peaked at $2.32M in Q3 2023. 67 funds tracked by Wall St. Rank hold MACK as of Q4 2023.

  • Centiva Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 187,803 Merrimack Pharmaceuticals, Inc. shares in Q4 2023, an estimated $2.32M.
  • Centiva Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2023 and held it in 1 quarter.
  • Centiva Capital's Merrimack Pharmaceuticals, Inc. position peaked at $2.32M in Q3 2023.
  • 67 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.